Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 18/20 | 0.56 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.48 |
| ▸ | PTGIR | P43119 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754412 | 0.92 | PTGDR2 (0.56) | PTGDR2AKR1A1AKR1B1PTGDRPTGIR | |
| SCHEMBL7205581 | 0.87 | AKR1B1 (0.55) | PTGDR2AKR1A1AKR1B1 | |
| SCHEMBL317185 | 0.82 | PTGDR2 (0.66) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL2100600 | 0.82 | AKR1B1 (0.53) | PTGDR2AKR1A1AKR1B1 | |
| SCHEMBL7755700 | 0.79 | PTGDR2 (0.65) | PTGDR2AKR1A1AKR1B1 | |
| SCHEMBL7755971 | 0.78 | PTGDR2 (0.50) | PTGDR2AKR1A1AKR1B1CYP2C9 | |
| SCHEMBL2098715 | 0.77 | AKR1B1 (0.70) | PTGDR2AKR1A1AKR1B1 | |
| SCHEMBL1757491 | 0.76 | PTGDR2 (0.73) | PTGDR2AKR1A1AKR1B1PTGDRCYP2C9 | |
| Water SCHEMBL5501664 | 0.76 | AKR1B1 (0.69) | PTGDR2AKR1A1AKR1B1 | |
| SCHEMBL7947673 | 0.75 | AKR1B1 (0.57) | PTGDR2AKR1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1205207-C | Substituted indolealkanoic acids | INST FOR PHARMACEUTICAL DESCOV (US) | 2005-06-08 | — | — | CN | disclosed |
| CN-1368883-A | Method for lowering serum glucose and triglyceride levels and inhibiting angiogenesis using indolealkanoic acids | INST PHARMACEUTICAL DISCOVERY (US) | 2002-09-11 | — | — | CN | disclosed |
| WO-2001051489-A2 | METHODS FOR LOWERING URIC ACID LEVELS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-07-19 | — | — | WO | disclosed |
| CN-1296485-A | Substituted indolealkanoic acids | INST FOR PHARM DISCOVERY INC (US) | 2001-05-23 | — | — | CN | disclosed |
| EP-1066283-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999050268-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 1999-10-07 | — | — | WO | disclosed |